{"id":"NCT00960076","sponsor":"AstraZeneca","briefTitle":"An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes","officialTitle":"18-Week, Multicenter, Randomized, Double-Blind 3b Trial to Evaluate Efficacy/Safety of Saxagliptin in Combo With Metformin XR 1500mg vs Metformin Uptitrated to 2000mg in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control After Diet/Exercise and a Stable Dose of Metformin XR 1500mg","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08","primaryCompletion":"2010-10","completion":"2010-10","firstPosted":"2009-08-17","resultsPosted":"2011-09-27","lastUpdate":"2011-09-27"},"enrollment":282,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Saxagliptin","otherNames":["Onglyza"]},{"type":"DRUG","name":"Metformin XR","otherNames":[]},{"type":"DRUG","name":"Metformin XR","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare reduction in A1C for subjects taking Saxagliptin and Metformin XR vs. uptitrated Metformin XR.","primaryOutcome":{"measure":"Change in HbA1c Level From Baseline to Week 18 (LOCF)","timeFrame":"Baseline to week 18","effectByArm":[{"arm":"Saxagliptin + Metformin","deltaMin":8.41,"sd":0.076},{"arm":"Metformin (DB) + Metformin (OL)","deltaMin":8.28,"sd":0.077}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":35,"countries":["United States","Colombia","Costa Rica","Mexico","Peru"]},"refs":{"pmids":["22192246"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":138},"commonTop":["Nasopharyngitis","Diarrhoea","Urinary Tract Infection"]}}